Literature DB >> 16401485

American Gastroenterological Association medical position statement on the management of hepatitis C.

Jules L Dienstag, J G McHutchison.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16401485     DOI： 10.1053/j.gastro.2005.11.011

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  38 in total

1.  Screening for hepatitis C in average and high-risk populations of Qatar using rapid point-of-care testing.

Authors:  Manik Sharma; Saad Al Kaabi; Anil K John; Nazeeh Al Dweik; Hameed Ullah Wani; Ragesh Babu Thandassary; Moutaz F Derbala; Khalid Al Ejji; Khaleel Sultan; Fuad Pasic; Munnera Al Mohannadi; Rafae Yacoub; Mohd Tariq Butt; Rajvir Singh
Journal:  United European Gastroenterol J       Date:  2015-08       Impact factor: 4.623

Review 2.  Hepatitis C infection with normal liver chemistry tests.

Authors:  Michael W Fried
Journal:  Clin Gastroenterol Hepatol       Date:  2008-04-14       Impact factor: 11.382

Review 3.  Current applications of therapeutic phlebotomy.

Authors:  Tarek Bou Assi; Elizabeth Baz
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

4.  Optimizing the dose and duration of therapy for chronic hepatitis C.

Authors:  Nipaporn Pichetshote; Erik Groessl; Helen Yee; Samuel B Ho
Journal:  Gut Liver       Date:  2009-03-31       Impact factor: 4.519

5.  The swinging thyroid in hepatitis C infection and interferon therapy.

Authors:  Huy A Tran
Journal:  BMJ Case Rep       Date:  2009-09-15

6.  Antiviral Candidates for Treating Hepatitis E Virus Infection.

Authors:  Natalie E Netzler; Daniel Enosi Tuipulotu; Subhash G Vasudevan; Jason M Mackenzie; Peter A White
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

7.  Bioelectrical impedance analysis for the evaluation of hepatic fibrosis in patients with chronic hepatitis C infection.

Authors:  Fadi Antaki; M Margaret French; Dilip K Moonka; Stuart C Gordon
Journal:  Dig Dis Sci       Date:  2007-11-13       Impact factor: 3.199

8.  Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.

Authors:  V Saxena; M M Manos; H S Yee; L Catalli; E Wayne; R C Murphy; V A Shvachko; M P Pauly; J Chua; A Monto; N A Terrault
Journal:  Aliment Pharmacol Ther       Date:  2014-03-24       Impact factor: 8.171

Review 9.  [Functional MR imaging of the liver].

Authors:  A Wibmer; R Nolz; M Trauner; A Ba-Ssalamah
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

10.  The Spectrum of Autoimmune Thyroid Disease in the Short to Medium Term Following Interferon-alpha Therapy for Chronic Hepatitis C.

Authors:  Huy A Tran; Glenn E M Reeves
Journal:  Int J Endocrinol       Date:  2009-08-31       Impact factor: 3.257
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.